Abstract
Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Current Pharmaceutical Design
Title:Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers
Volume: 19 Issue: 17
Author(s): Satoshi Imaizumi, Shin-ichiro Miura, Eiji Yahiro, Yoshinari Uehara, Issei Komuro and Keijiro Saku
Affiliation:
Keywords: Angiotensin II type receptor blocker, cardiovascular disease, molecular structures, class-specific effects, molecule-specific effects.
Abstract: Angiotensin II (Ang II) type 1 (AT1) receptor is a member of the G protein-coupled receptor superfamily and contains 359 amino acids. AT1 receptor blockers (ARBs, e.g., eprosartan, losartan, candesartan, valsartan, telmisartan, olmesartan, irbesartan, and azilsartan) have been developed and are available for clinical use, and basic and clinical studies have shown that ARBs are useful for preventing the development of cardiovascular disease. While most ARBs have common molecular structures (biphenyl-tetrazol and imidazole groups), they also show slightly different structures. Some of the benefits conferred by ARBs may not be class-specific effects, and instead may be molecule-specific effects. Their common molecular structures are thought to be responsible for their class effects, whereas their slightly different structures may be important for promoting molecule-specific effects. This review focuses on current evidence regarding the class- and molecule-specific differential effects of ARBs from basic experiments to clinical settings.
Export Options
About this article
Cite this article as:
Imaizumi Satoshi, Miura Shin-ichiro, Yahiro Eiji, Uehara Yoshinari, Komuro Issei and Saku Keijiro, Class- and Molecule-specific Differential Effects of Angiotensin II Type 1 Receptor Blockers, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170005
DOI https://dx.doi.org/10.2174/1381612811319170005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews EDITOR’S PERSPECTIVE [The Challenges for Drug Development: Cytokines, Genes, and Stem Cells]
Current Neurovascular Research Chronic Kidney Disease and the Risk of Cardiovascular Disease Events: A Community-Based Approach
Vascular Disease Prevention (Discontinued) Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in <i>Helicobacter Pylori</i> Eradication
Anti-Infective Agents Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews Current Trends in Using Internet and Mobile Technology to Support the Treatment of Substance Use Disorders
Current Drug Abuse Reviews Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not Related to Disease Severity
Current Rheumatology Reviews Stimulant-Related Psychosis in ADHD Treatment: An Update for Past 10 Years
Current Psychopharmacology Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Antioxidants in Peripheral Arterial Disease
Current Drug Targets New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Current Medicinal Chemistry Bone Mineral Density in Type 2 Diabetes Patients with Charcot Arthropathy
Current Diabetes Reviews Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis
Infectious Disorders - Drug Targets High Blood Pressure Combined with Sedentary Behavior in Young People: A Systematic Review
Current Hypertension Reviews Fish Gelatin Hydrolysates as Antioxidant, Antihypertensive, and Antidiabetic: The Plausible Mechanisms
Mini-Reviews in Organic Chemistry Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews 25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages
Current Pharmaceutical Design Combination of Fenofibrate with Non-Statin Drug Regimens
Current Pharmaceutical Design